ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Associations of Type 2 Diabetes with Risk of Overall and Site-Specific Cancers in a Cohort of Predominantly Low-Income Racially Diverse Populations.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe prevalence of type 2 diabetes (T2D) is higher in Black than in White Americans, and individuals with T2D have an increased cancer risk. We investigated the association of T2D with the risk of all cancers combined and 21 site-specific cancers among predominantly low-income participants who experienced a disproportionately high risk of both T2D and cancer.
methodsThe study included 76,121 participants (mean age, 52.0 years; 67.2% Black) from the Southern Community Cohort Study. T2D was ascertained at the baseline survey. Incident cancer was ascertained via linkage to state cancer registries. Cox proportional hazards models were used to estimate the associations between T2D and cancer after adjusting for confounders.
resultsAmong participants, 21.2% (N = 16,137) had baseline T2D, and 9.7% (N = 7,376) were diagnosed with incident cancer. Compared with individuals without T2D, individuals with T2D had a significantly elevated risk of all cancers combined (HR, 1.07; 95% confidence interval, 1.01-1.13) and several site-specific cancers, including cancers of the stomach, colorectum, pancreas, liver/intrahepatic bile duct, kidney, and renal pelvis as well as leukemia. The significant association for most cancers was largely observed within 15 years after T2D diagnosis, except for cancer of the pancreas and liver/intrahepatic bile duct, for which elevated risks remain statistically significant 15 to 30 years after T2D diagnosis.
conclusionsT2D was associated with the risk of overall and certain site-specific cancers in this predominant low-income population. IMPACT: Preventive measures to reduce the burden from T2D could help reduce the risk of overall cancer and several site-specific cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.